Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email

NKGen Biotech (NKGN) News Today

→ Elon to Transform U.S. Economy? (From Porter & Company) (Ad)
Free NKGN Stock Alerts
$1.12
-0.01 (-0.88%)
(As of 05/17/2024 08:54 PM ET)
Compare
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media
May 16, 2024 | globenewswire.com
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
April 29, 2024 | marketwatch.com
NKGen Biotech Shares Rise 15% After FDA Clears Application for Parkinson's Disease Therapy
April 29, 2024 | markets.businessinsider.com
NKGen Biotech: FDA Clears IND Application For SNK01 NK Cell Therapy - Quick Facts
April 29, 2024 | finance.yahoo.com
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
April 29, 2024 | globenewswire.com
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's Disease
April 25, 2024 | finance.yahoo.com
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
April 25, 2024 | globenewswire.com
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
April 24, 2024 | globenewswire.com
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 22, 2024 | finance.yahoo.com
Replicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
April 22, 2024 | finance.yahoo.com
What's Going On With Nano-Cap NKGen Biotech Stock On Monday?
April 18, 2024 | finance.yahoo.com
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
April 18, 2024 | globenewswire.com
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit
April 17, 2024 | investorplace.com
NKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023
April 11, 2024 | globenewswire.com
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
March 25, 2024 | globenewswire.com
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference
March 22, 2024 | investing.com
NKGen Biotech appoints new chairperson amid leadership shuffle
March 6, 2024 | investorplace.com
Why Is NKGen Biotech (NKGN) Stock Up 62% Today?
March 4, 2024 | finance.yahoo.com
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference
March 4, 2024 | globenewswire.com
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference
February 9, 2024 | msn.com
Alana McNulty Exits NKGen Biotech’s Board and Committees
February 7, 2024 | finance.yahoo.com
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
January 3, 2024 | investing.com
NKGen Biotech Inc (NKGN)
December 29, 2023 | finance.yahoo.com
NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial
December 28, 2023 | finance.yahoo.com
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease
December 27, 2023 | marketwatch.com
NKGen Biotech Gets Clearance to Begin Alzheimer's Disease Treatment Trials in Canada
December 27, 2023 | markets.businessinsider.com
NKGen Biotech Receives Clearance For SNK01 NK Cell Therapy Clinical Trial From Health Canada
December 27, 2023 | finance.yahoo.com
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
November 30, 2023 | seekingalpha.com
NKGN NKGen Biotech, Inc.
November 15, 2023 | seekingalpha.com
NKGen Biotech GAAP EPS of -$2.48
November 14, 2023 | finance.yahoo.com
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
November 7, 2023 | morningstar.com
NKGen Biotech Inc NKGN
November 7, 2023 | finance.yahoo.com
NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
November 7, 2023 | finance.yahoo.com
NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
November 7, 2023 | finance.yahoo.com
NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 7, 2023 | finance.yahoo.com
NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
November 7, 2023 | finance.yahoo.com
NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.
November 7, 2023 | finance.yahoo.com
NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 27, 2023 | investorplace.com
Why Is NKGen Biotech (NKGN) Stock Up 18% Today?
Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

NKGN Media Mentions By Week

NKGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NKGN
News Sentiment
▼
0.00

0.42
▲
Average
Medical
News Sentiment

NKGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NKGN Articles
This Week
▼
1

1
▲
NKGN Articles
Average Week

Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NYSE:NKGN) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Urgent Nvidia Warning
Altimetry
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Elon’s New Device is About to Shock the World
InvestorPlace
Most important medical advance in 100 years
The Oxford Club